Novavax Raises 2026 Revenue Guidance After Sanofi Vaccine Milestone
+2 new sources since this summary was written
Novavax reported third-quarter 2026 revenue of $68.3M and a net loss of 19 cents per share. The company raised full-year 2026 Non-GAAP Adjusted Total Revenue guidance by $145 million to a $400 million midpoint and improved expense guidance. Sanofi’s European Phase 3 influenza-COVID-19 vaccine trial triggered a $125 million milestone for Novavax, while Sanofi intends to begin a U.S. Phase 3 trial in 2027.
Why it matters
The milestone increases Novavax’s reported 2026 revenue framework and provides additional potential payments, including $225 million upon a qualifying U.S. commercial launch and $75 million after expected manufacturing technology transfer in mid-2027. Those future payments remain dependent on Sanofi’s clinical, regulatory and commercial milestones.
Key facts
- 1Third-quarter 2026 revenue was $68.3M, and the company reported a loss of 19 cents per share. finance.yahoo.com
- 2Novavax raised full-year 2026 Non-GAAP Adjusted Total Revenue guidance by $145 million to $400 million at the midpoint. prnewswire.com
- 3Novavax received a $125 million milestone in October after Sanofi initiated its Phase 3 influenza-COVID-19 combination vaccine trial in Europe. prnewswire.com
- 4Sanofi intends to initiate a U.S. Phase 3 influenza-COVID-19 combination vaccine trial in 2027, and Novavax is eligible for an additional $225 million milestone upon a U.S. commercial launch. prnewswire.com
- 5Completion of Sanofi’s manufacturing technology transfer for Nuvaxovid is expected in mid-2027 and would trigger a $75 million milestone payment to Novavax. prnewswire.com
Summary written by AlphAI AI Desk from 14 of 14 sources. Not investment advice. Figures are as stated by the linked sources.